Zealthy Streamlines Coverage for Wegovy and Ozempic; Viking Trials Propel Obesity Stock 8%
NVO•Zealthy has expanded its insurance coordination program to streamline prior-authorizations and coverage for GLP-1 weight-loss drugs including Wegovy, Ozempic, Zepbound, and Mounjaro, potentially easing patient access and reducing administrative delays. Viking Therapeutics shares jumped nearly 8% on June 23 after announcing Q3 data plans for its maintenance study of oral and injectable VK2735, with pivotal late-stage trials slated for H2 2026.
1. Zealthy Expands GLP-1 Insurance Coordination
Zealthy has broadened its insurance-coordination program to support patients prescribed GLP-1 medications like Wegovy, Ozempic, Zepbound and Mounjaro by automating prior-authorizations, insurance verification and coverage determinations while acknowledging that final approval and patient cost decisions remain with insurers.
2. Viking Therapeutics’ VK2735 Pipeline Boosts Obesity Market Pressure
Shares of Viking Therapeutics jumped nearly 8% on June 23 following confirmation that its 180-patient maintenance study will generate data in Q3 and that pivotal late-stage trials of both oral and injectable VK2735 are set to begin in the second half of 2026, potentially offering a dual-track alternative to current GLP-1 therapies.
